A federal judge has dismissed Amgen’s lawsuit against Colorado’s Prescription Drug Affordability Board, allowing the state to move forward with setting price ceilings on prescription drugs, The Denver Post reported March 31.
U.S. District Judge Nina Wang ruled March 28 that a price ceiling set by Colorado wouldn’t limit what Amgen could charge for its drugs. The board can declare medications “unaffordable” and set an “upper payment limit” capping the amount patients, pharmacies and insurers pay for a drug in Colorado.
Amgen sued the board in March 2024 after it deemed autoimmune injectable Enebral unaffordable for Colorado patients.
Colorado is the first state to attempt setting a price ceiling on any drug. The board is set to begin the price-setting process in mid-April and could decide not to establish a ceiling.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
